The lack of access to testing in areas outside of Metro Manila remains a significant challenge, with potentially devastating consequences for conditions such as cervical cancer. The prohibitive cost of diagnostics continues to be a significant barrier to access, and consequently, to the diagnosis and treatment of the country's priority diseases. This is despite the country undertaking commendable efforts, such as ongoing efforts to implement its Universal Health Care Act and ratification of the RCEP.
To empower communities and promote informed decision-making, services and programmes in the Philippines will have to be continuously tailored to the needs of affected populations in different settings, including centralised testing with high volume testing labs and treatment in urban and periurban settings and decentralised testing and treatment in rural and remote areas. For the betterment of health for individuals, it is high time that health leaders and regulators in the Philippines work hand in hand with private sectors to accelerate ease of access to better and strengthened diagnostic systems.
In this panel, the various stakeholders will discuss the following:
Representative of the 1st District of Iloilo and former DOH secretary, House of Representatives
Country Representative at UNFPA Philippines
President at Philippine Council for Quality Assurance in Clinical Laboratories
GM at Roche Diagnostics Philippines
Country Manager at Abbott Rapid Diagnostics
MD, PhD, Trustee Director of Cervical Cancer Prevention Network (CECAP) and Philippines Gynecologic Oncologist, Department of OB-Gyne and Cancer Institute, University of the Philippines College of Medicine, Philippine General Hospital
MD, Lead of Research Institute for Tropical Medicine and Member of DOH at NASPCP Technical Working Group, Department of Health; NASPCP, National AIDS/STI Prevention and Control Program
President at Philippine Academic Consortium for Public Health
Associate Director, Healthcare, Southeast Asia of APCO Worldwide